Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1392

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 9A
Chunk 1392
---
 NEOs during the periods presented.

Compensation Actually Paid and Cumulative TSR

The chart below shows the relationship between
the compensation actually paid to our PEOs and the average compensation actually paid to our non-PEO NEOs, on the one hand, to the Company’s
cumulative TSR over the three years presented in the table, on the other.

All information provided above under the “Item
402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and
irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such
information by reference.

 76 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
INDEPENDENCE

The following describes all
transactions since April 1, 2023, and all proposed transactions, in which we were or are to be a participant and the amount involved
exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years,
and in which any related person had or will have a direct or indirect material interest. In making such decisions our Audit Committee
considers and approves or disapproves any related party transaction as defined under SEC Regulation Item 404, to the extent required
by SEC regulations.

Separation Agreement with Former CEO

In connection with Charles
J. Fisher, Jr. M.D.’s resignation as the Company’s Chief Executive Officer, effective November 2023, (the “Fisher Separation
Date”), in accordance with the terms of his Executive Employment Agreement with the Company, dated as of October 30, 2020 (the “Fisher
Employment Agreement”), and pursuant to Dr. Fisher’s Separation Agreement with the Company, effective as of November 27, 2023
(the “Fisher Separation Agreement”), the Company will provide Dr. Fisher with (1) cash severance equivalent to twelve months
of Dr. Fisher’s base salary in effect as of the Separation Date, subject to standard payroll deductions and withholdings, payable
over the Company’s regular payroll schedule over the twelve months following the Separation Date; (2) the accelerated vesting on
fifty percent (50%)